Akero Therapeutics Inc (NASDAQ: AKRO) is -9.63% lower on its value in year-to-date trading and has touched a low of $15.32 and a high of $37.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AKRO stock was last observed hovering at around $24.01 in the last trading session, with the day’s gains setting it 1.13%.
Currently trading at $25.14, the stock is -5.81% and -14.61% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing 4.71% at the moment leaves the stock -3.01% off its SMA200. AKRO registered 15.32% gain for a year compared to 6-month gain of -7.16%. The firm has a 50-day simple moving average (SMA 50) of $29.4425 and a 200-day simple moving average (SMA200) of $25.921375.
The stock witnessed a -13.99% loss in the last 1 month and extending the period to 3 months gives it a -19.03%, and is 1.21% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.79% over the week and 6.00% over the month.
Akero Therapeutics Inc (AKRO) has around 56 employees, a market worth around $1.75B and $0.00M in sales. Distance from 52-week low is 64.10% and -32.05% from its 52-week high. The company has generated returns on investments over the last 12 months (-30.65%).
The EPS is expected to shrink by -34.94% this year, but quarterly earnings will post 0.00% year-over-year. Quarterly sales are estimated to shrink 0.00% in year-over-year returns.
Akero Therapeutics Inc (AKRO) Top Institutional Holders
247.0 institutions hold shares in Akero Therapeutics Inc (AKRO), with institutional investors hold 112.55% of the company’s shares. The shares outstanding are 69.61M, and float is at 58.32M with Short Float at 5.67%. Institutions hold 106.27% of the Float.
The top institutional shareholder in the company is JANUS HENDERSON GROUP PLC with over 6.88 million shares valued at $161.28 million. The investor’s holdings represent 11.5942% of the AKRO Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.59 million shares valued at $131.06 million to account for 9.4197 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.43 million shares representing 9.159% and valued at over $127.43 million, while GENERAL ATLANTIC, L.P. holds 8.8251 of the shares totaling 5.23 million with a market value of $122.79 million.
Akero Therapeutics Inc (AKRO) Insider Activity
The most recent transaction is an insider sale by Young Jonathan, the company’s Chief Operating Officer. SEC filings show that Young Jonathan sold 10,000 shares of the company’s common stock on Jan 02 ’25 at a price of $28.03 per share for a total of $0.28 million. Following the sale, the insider now owns 0.22 million shares.
Still, SEC filings show that on Dec 16 ’24, Lamy Patrick (Senior VP, Commercial Strategy) disposed off 1,000 shares at an average price of $29.13 for $29130.0. The insider now directly holds 34,258 shares of Akero Therapeutics Inc (AKRO).
